Hong Zhang

Hong Zhang

Translational oncology, biomarker, statistical genetics, pharmacogenetics and statistical theories of signals aggregation.

Publications (Google Scholar)

† equal contribution; * corresponding author.

Statistical theory and method

  1. Hong Zhang, Ming Liu, John Landers and Zheyang Wu. “Optimal weighting for integrative association tests: application to whole-genome sequencing studies”.
    Accepted. Annals of Applied Statistics, 2026+.

  2. Hong Zhang*, Jie Pu, Shibing Deng, Haitao Chu, Satrajit Roychoudhury and Douglas Robinson. “Study duration prediction for clinical trials with time-to-event endpoints accounting for heterogeneous population”.
    Journal of Biopharmaceutical Statistics, (2025), doi: 10.1080/10543406.2025.2489294.

  3. Hong Zhang, Devan Mehrotra and Judong Shen. “AWOT and CWOT for genotype and genotype by treatment interaction joint analysis in pharmacogenetics GWAS”.
    Bioinformatics, vol. 39, no. 1 (2023), doi: 10.1093/bioinformatics/btac834.

  4. Hong Zhang, Ming Liu, Jiashun Jin and Zheyang Wu. “Signal-noise ratio of genetic associations and statistical power of SNP-set tests”.
    Annals of Applied Statistics, vol. 17 (2023), doi: 10.1214/22-AOAS1725.

  5. Song Zhai†, Hong Zhang†, Devan Mehrotra and Judong Shen. “Pharmacogenomics Polygenic risk score for drug response prediction using PRS-PGx methods”.
    Nature Communications, 13:5278 (2022), doi: 10.1038/s41467-022-32407-9.

  6. Hong Zhang and Zheyang Wu. “A generalized family of Fisher’s combination tests and their null distributions under correlation”.
    Biometrics, vol. 79 (2022), doi: 10.1111/biom.13634.

  7. Hong Zhang*, Judong Shen and Zheyang Wu. “A fast and accurate approximation to the distributions of quadratic forms of Gaussian variables”.
    Journal of Computational and Graphical Statistics, vol. 31 (2022), doi: 10.1080/10618600.2021.2000423.

  8. Hong Zhang and Zheyang Wu. “The general goodness-of-fit tests for correlated data”.
    Computational Statistics and Data Analysis, vol. 167 (2022), doi: 10.1016/j.csda.2021.107379.

  9. Xiaohui Chen, Hong Zhang, Ming Liu, Hong-Wen Deng and Zheyang Wu. “Simultaneous detection of novel genes and SNPs by adaptive p-value combination”.
    Frontiers in Genetics, vol. 13 (2022), doi: 10.3389/fgene.2022.1009428.

  10. Hong Zhang*, Qing Li, Devan V. Mehrotra and Judong Shen. “CauchyCP: a powerful test under non-proportional hazards using Cauchy combination of change-point Cox regressions”.
    Statistical Methods in Medical Research, vol. 30, no. 11 (2021), doi: 10.1177/09622802211037076.

  11. Hong Zhang, Tiejun Tong, John Landers and Zheyang Wu. “TFisher tests: optimal and adaptive thresholding for combining $p$-values”.
    Annals of Applied Statistics, vol. 14 (2020), doi: 10.1214/19-AOAS1302.

  12. Hong Zhang, Jiashun Jin and Zheyang Wu. “Distributions and statistical power of optimal signal detection methods in finite samples”.
    IEEE Transactions on Signal Processing, vol. 68 (2020), doi: 10.1109/TSP.2020.2967179.

  13. Hong Zhang, Ni Zhao, Devan Mehrotra and Judong Shen. “Composite kernel association test (CKAT) for SNP-set joint analysis of genotype and genotype-by-treatment interaction in pharmacogenetics studies”.
    Bioinformatics, vol. 36, no. 10 (2020), doi: 10.1093/bioinformatics/btaa125.

  14. Lan Luo, Judong Shen, Hong Zhang, Aparna Chhibber, Devan Mehrotra and Zheng-zheng Tang. “Multi-trait analysis of rare-variant association summary statistics using MTAR”.
    Nature Communications, 11:2850, (2020), doi: 10.1038/s41467-020-16591-0.

Biomedical application: Peer-Reviewed Publications

  1. Sujana Movva, …, Hong Zhang, …, Sant Chawla. “A Phase II study of TTI-621 in combination with doxorubicin in patients with unresectable or metastatic high-grade leiomyosarcoma”.
    Accepted, British Journal of Cancer, 2026+.

  2. Debu Tripathy, Joanne Blum, Hong Zhang, …, Aditya Bardia. “Circulating tumor DNA genotyping of intrinsic and accquired alterations in patients with advanced breast cancer receiving palbociclib: biomarker results from the POLARIS study”.
    JCO Precision Oncology, vol. 9 (2025), doi: 10.1200/PO-24-00810.

  3. Chibber Aparna†, Lingkang Huang†, Hong Zhang†, et al. “Germline human leukocyte antigen landscape and efficacy of pembrolizumab monotherapy across solid tumor types”.
    Immunity, vol. 55, no. 1 (2022), doi: 10.1016/j.immuni.2021.12.006.

  4. Hong Zhang, Aparna Chhibber, Peter Shaw, Devan Mehrotra and Judong Shen. “A statistical perspective on baseline adjustment in pharmacogenomic genome-wide association studies of quantitative change”.
    npj Genomic Medicine, vol. 7, no. 33 (2022), doi: 10.1038/s41525-022-00303-2.

  5. Hong Zhang, and Roger Lui. “Releasing Wolbachia-infected Aedes aegypti to prevent the spread of dengue virus: a mathematical study”.
    Infectious Disease Modelling, vol. 5 (2020), doi: 10.1016/j.idm.2019.12.004.

Biomedical application: Scientific Abstracts

  1. Antonio Giordano, Feng Liu, Whijae Loh, Hong Zhang, …, Timothy Yap. “Pharmacodynamic effects of the first-in-class CDK4-selective inhibitor atirmociclib (PF-07220060) in combination with endocrine therapy in tumors of patients with HR+/HER2- metastatic breast cancer”.
    Clinical Cancer Research, 32 (4_Supplement) (2026), doi: 10.1158/1557-3265.SABCS25-PS1-10-25.

  2. Peter Schmid, Manish Sharma, Antonio Giordano, …, Hong Zhang, …, Timothy Yap. “Effect of atirmociclib plus endocrine therapy (ET) on serum thymidine kinase activity (TKa) in a phase 1 study of patients with HR+/HER- metastatic breast cancer (mBC)”.
    ESMO Breast Cancer (2025), doi: 10.1016/j.esmoop.2025.104644.

  3. Timothy Yap, Feng Liu, Hong Zhang, …, Manish Sharma. “Longitudinal circulating tumor DNA (ctDNA) dynamics in phase I/IIa study of the first-in-class CDK4-selective inhibitor, PF-07220060, in combination with endocrine therapy in patients with HR+/HER2- metastatic breast cancer (mBC) who progressed on prior CDK4/6 inhibitors”.
    Annals of Oncology, vol. 35, suppl 392-393 (2024), doi: 10.1016/j.annonc.2024.08.361.

  4. John Timmerman, David Lavie, Nathalie Johnson, …, Hong Zhang, …, Alex Herrera. “Favezelimab (anti-LAG-3) plus pembrolizumab in patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) after anti-PD-1 treatment: An open-label phase 1/2 study”.
    Journal of Clinical Oncology, vol. 40, no. 16_suppl (2022), doi: 10.1200/JCO.2022.40.16_suppl.7545.

Preprint

  1. Xiaohui Chen, Fangfang Wang, Hong Zhang, and Zheyang Wu. “On Correlation Robustness of Supremum-based $p$-Value Combination Tests”.
    In Revision. Statistica Sinica, 2026+.